To sum up, this study not only provides new ideas for the development of novel tumor-targeted AGT inhibitors, but also demonstrated that both the reductive activity and the hypoxia selectivity should be considered in the design of hypoxia-targeted prodrugs. The gene discussed is AGT; the disease is neoplasm.